GlassScriptPhysician profile
Michelle O Pasamba
NPI 1548552888
$306.73
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $97.69 · 2021: $87.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $94.37 | 2019-2021 | |
| Chiesi USA, INC. | $84.24 | 2019-2021 | |
| Avanos Medical | $28.64 | 2019 | |
| Merck Sharp & Dohme LLC | $28.34 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.96 | 2020-2021 | |
| Acelrx Pharmaceuticals, INC. | $14.91 | 2019 | |
| Endo Pharmaceuticals INC. | $14.68 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Pasamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.